273 assets in Metastatic Malignant Neoplasm

Therapeutic assets addressing Metastatic Malignant Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Binimetinib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Ceralasertib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Darolutamide Metastatic Malignant Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	CCC (55)
Durvalumab Metastatic Malignant Neoplasm	I-Mab Biopharma US Limited	P2	CCC (55)
Entrectinib Metastatic Malignant Neoplasm	Seoul National University Bundang Hospital	P2	CCC (55)
Enzalutamide Metastatic Malignant Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	CCC (55)
Everolimus Metastatic Malignant Neoplasm	Fudan University	P2	CCC (55)
Givastomig Metastatic Malignant Neoplasm	I-Mab Biopharma US Limited	P2	CCC (55)
Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor Receptor Type Vegfr-2 Extracellular Domain) (Human Monoclonal Imc-1121B .Gamma.-Chain), Disulphide With Human Monoclonal Imc-1121B .Kappa.-Chain, Dimer Metastatic Malignant Neoplasm	Xiuning Le	P2	CCC (55)
Nab-Sirolimus Metastatic Malignant Neoplasm	Mirati Therapeutics Inc.	P2	CCC (55)
Niraparib Metastatic Malignant Neoplasm	Tempus AI	P2	CCC (55)
Olaparib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Palbociclib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Talazoparib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Trametinib Metastatic Malignant Neoplasm	OHSU Knight Cancer Institute	P1/2	CCC (55)
Trastuzumab Deruxtecan Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (55)
Adavosertib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (54)
Alnodesertib Metastatic Malignant Neoplasm	Artios Pharma Ltd	P2	CCC (54)
Bezuclastinib Metastatic Malignant Neoplasm	Cogent Biosciences, Inc.	P3	CCC (54)
Denosumab Metastatic Malignant Neoplasm	Kelly Fitzgerald, MD	P2	CCC (54)
Gm-Csf Metastatic Malignant Neoplasm	Rampart Health, L.L.C.	P2	CCC (54)
Prednisolone Metastatic Malignant Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	CCC (54)
Retifanlimab Metastatic Malignant Neoplasm	Incyte Corporation	P1/2	CCC (54)
Vemurafenib Metastatic Malignant Neoplasm	Seoul National University Bundang Hospital	P2	CCC (54)
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer Metastatic Malignant Neoplasm	ETOP IBCSG Partners Foundation	P2	CCC (53)
Tacrolimus Metastatic Malignant Neoplasm	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	P2	CCC (53)
Futibatinib Metastatic Malignant Neoplasm	Taiho Oncology, Inc.	P2/3	CCC (52)
Anamorelin Metastatic Malignant Neoplasm	M.D. Anderson Cancer Center	P2	CCC (51)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Metastatic Malignant Neoplasm	Fudan University	P2	CCC (51)
Apalutamide Metastatic Malignant Neoplasm	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	P2	CCC (51)
Avapritinib Metastatic Malignant Neoplasm	M.D. Anderson Cancer Center	P2	CCC (51)
e7 tcr-t cells Metastatic Malignant Neoplasm	Christian Hinrichs	P2	CCC (51)
FFNP Metastatic Malignant Neoplasm	University of Wisconsin, Madison	P2	CCC (51)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Metastatic Malignant Neoplasm	Haihua Yuan	P2	CCC (51)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Cdh6(Cadherin 6, K-Cadherin (Foetal Kidney), Cadherin 6 Type 2)], Humanized Monoclonal Antibody Conjugated To Deruxtecan, Comprising A Linker And A Camptothecin Derivative Metastatic Malignant Neoplasm	Daiichi Sankyo	P2	CCC (51)
Ipatasertib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Larotrectinib Metastatic Malignant Neoplasm	M.D. Anderson Cancer Center	P2	CCC (51)
Nilotinib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
np137 Metastatic Malignant Neoplasm	Centre Leon Berard	P2	CCC (51)
ose2101 Metastatic Malignant Neoplasm	GERCOR - Multidisciplinary Oncology Cooperative Group	P2	CCC (51)
Paxalisib Metastatic Malignant Neoplasm	Alliance for Clinical Trials in Oncology	P2	CCC (51)
Ptvg-Ar Metastatic Malignant Neoplasm	University of Wisconsin, Madison	P2	CCC (51)
Ptvg-Hp Metastatic Malignant Neoplasm	University of Wisconsin, Madison	P2	CCC (51)
Selumetinib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Sotorasib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
Telaglenastat Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P2	CCC (51)
TIL Metastatic Malignant Neoplasm	City of Hope Medical Center	P1/2	CCC (51)
Veliparib Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (51)
Zanzalintinib Metastatic Malignant Neoplasm	Kelly Fitzgerald, MD	P2	CCC (51)
Navitoclax Metastatic Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (50)

Showing 51 to 100 of 273 assets

PreviousPage 2 of 6Next